Anti-Matriptase-2 Antibodies for Iron Overload Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for iron overload conditions such as beta-thalassaemia and myelodysplastic syndrome (MDS) are inadequate, as they do not address the underlying disease pathology and often have undesirable side effects, such as kidney failure and toxic neutropenia, and fail to achieve transfusion independence.
Innovation Solution
Development of binder polypeptides, particularly antibodies, that specifically target and inhibit the activity of matriptase-2 (MTP-2), a serine protease that inhibits BMP-SMAD signaling and reduces hepcidin expression, thereby reducing iron uptake and release from storage cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If current treatments for iron overload are used, then iron levels are reduced, but kidney failure and toxic neutropenia occur
Solution Approach 1:
The patent uses hepcidin as an intermediary molecule to regulate iron metabolism. Instead of directly removing iron with chelators, the invention modulates hepcidin levels to naturally control iron absorption and release, thereby reducing iron overload without the toxic side effects of conventional chelation therapy
Solution Approach 2:
The patent replaces the mechanical/chemical approach of iron chelation with a biological regulatory approach. By targeting the hepcidin pathway (a natural hormonal regulator), the invention substitutes direct iron binding with a physiologically-based regulatory mechanism that avoids toxicity
2Quantity of substance
If current treatments for iron overload are used, then iron levels are reduced, but transfusion independence is not achieved
Solution Approach 1:
The patent employs preliminary action by modulating hepcidin levels before iron overload becomes severe and before transfusion dependence is established. By early intervention in the iron regulatory pathway, the treatment prevents the progression to transfusion dependence rather than merely managing established iron overload
3Quantity of substance
If MTP-2 activity is increased, then iron absorption is enhanced, but iron overload and toxic accumulation occur
Solution Approach 1:
The patent restores the natural feedback mechanism of iron regulation by modulating hepcidin levels. Hepcidin normally provides negative feedback to control iron absorption and release; by replenishing or activating hepcidin, the system regains its ability to self-regulate iron levels, preventing both deficiency and toxic accumulation
Data Source
AI summary
Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.